DG3173

DRUG5 trials

Sponsors

Aspireo Pharmaceuticals Limited

Conditions

AcromegalyHealthy

Phase 1

Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173

CompletedNCT02217839

Aspireo Pharmaceuticals LimitedHealthy

Start: 2012-04-30Updated: 2014-08-15

Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173

CompletedNCT02217826

Aspireo Pharmaceuticals LimitedHealthy

Updated: 2014-08-19

Single Ascending Dose Tolerability Study of DG3173

CompletedNCT02217488

Aspireo Pharmaceuticals LimitedHealthy

Start: 2008-05-31Updated: 2014-08-15

Phase 2

The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics

CompletedNCT02217800

Aspireo Pharmaceuticals LimitedAcromegaly

Start: 2013-11-30End: 2016-05-31Updated: 2018-02-15

Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.

CompletedNCT02235987

Aspireo Pharmaceuticals LimitedAcromegaly

Start: 2012-10-31End: 2014-04-30Updated: 2018-02-15